1 week Ago By ABMN Staff
LENZ Therapeutics ( NASDAQ:LENZ – Get Free Report ) and SOPHiA GENETICS ( NASDAQ:SOPH – Get Free Report ) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends and earnings. Earnings and Valuation This table compares LENZ Therapeutics and SOPHiA GENETICS’s top-line revenue, earnings per share and valuation. SOPHiA GENETICS has higher revenue and earnings than LENZ Therapeutics.
Insider & Institutional Ownership Risk and Volatility LENZ Therapeutics has a beta of 0.39, suggesting that its stock price is 61% less volatile than the S&P 500. Comparatively, SOPHiA GENETICS has a beta of 1.
04, suggesting that its stock price is 4% more volatile than the S&P 500. Profitability This table compares LENZ Therapeutics and SOPHiA GENETICS’s net margins, return on equity and return on assets. Analyst Recommendations This is a summary of current ratings and recommmendations for LENZ Therapeutics and SOPHiA GENETICS, as reported by MarketBeat.
com. LENZ Therapeutics presently has a consensus price target of $35.00, indicating a potential upside of 47.
06%. SOPHiA GENETICS has a consensus price target of $6.50, indicating a potential upside of 73.
33%. Given SOPHiA GENETICS’s higher probable upside, analysts plainly believe SOPHiA GENETICS is more favorable than LENZ Therapeutics. About LENZ Therapeutics ( Get Free Report ) LENZ Therapeutics, Inc.
, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
About SOPHiA GENETICS ( Get Free Report ) SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.
SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland. Receive News & Ratings for LENZ Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LENZ Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .
.
